Specificity and effector mechanisms of autoantibodies in congenital heart block

Current Opinion in Immunology

Volumn 18, Issue 6, 2006, Pages 690-696

  Wahren Herlenius, Marie ^a   Sonesson, Sven Erik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; EPITOPE; FLUORINATED STEROID; LA ANTIBODY; RO ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; APOPTOSIS; CALCIFICATION; CALCIUM HOMEOSTASIS; CONGENITAL HEART BLOCK; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART ATRIOVENTRICULAR NODE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HIGH RISK PREGNANCY; HUMAN; PATHOGENESIS; PLACENTA; PREGNANCY; PREGNANT WOMAN; PROTEIN TRANSPORT; REVIEW; TISSUE INJURY;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; FETAL DISEASES; FETAL THERAPIES; HEART BLOCK; HUMANS; MYOCYTES, CARDIAC; PREGNANCY; STEROIDS, FLUORINATED;

EID: 33750322856     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.09.012     Document Type: Review

References (53)

1. Litsey S.E., Noonan J.A., O'Connor W.N., Cottrill C.M., and Mitchell B. Maternal connective tissue disease and congenital heart block. Demonstration of immunoglobulin in cardiac tissue. N Engl J Med 312 (1985) 98-100
2. Clancy R.M., Kapur R.P., Molad Y., Askanase A.D., and Buyon J.P. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 50 (2004) 173-182
3. Michaelsson M., and Engle M.A. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 4 (1972) 85-101
4. Waltuck J., and Buyon J.P. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 120 (1994) 544-551
5. Nield L.E., Silverman E.D., Taylor G.P., Smallhorn J.F., Mullen J.B., Silverman N.H., Finley J.P., Law Y.M., Human D.G., Seaward P.G., et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 105 (2002) 843-848
6. Jaeggi E.T., Hamilton R.M., Silverman E.D., Zamora S.A., and Hornberger L.K. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 39 (2002) 130-137
7. Moak J.P., Barron K.S., Hougen T.J., Wiles H.B., Balaji S., Sreeram N., Cohen M.H., Nordenberg A., Van Hare G.F., Friedman R.A., et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 37 (2001) 238-242
8. Buyon J.P., Hiebert R., Copel J., Craft J., Friedman D., Katholi M., Lee L.A., Provost T.T., Reichlin M., Rider L., et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 31 (1998) 1658-1666
9. Sonesson S.E., Salomonsson S., Jacobsson L.A., Bremme K., and Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 50 (2004) 1253-1261. This prospective study demonstrates that signs of first-degree heart block occur in as many as one third of Ro52-positive pregnancies, but that it is is spontaneously reversible. The study also documents the first case progressing from first-degree block to third degree block, substantiating the concept that congenital heart block is a progressively developing disease.
10. Rosenthal D., Druzin M., Chin C., and Dubin A. A new therapeutic approach to the fetus with congenital complete heart block: preemptive, targeted therapy with dexamethasone. Obstet Gynecol 92 (1998) 689-691
11. Theander E., Brucato A., Gudmundsson S., Salomonsson S., Wahren-Herlenius M., and Manthorpe R. Primary Sjögren's syndrome - treatment of fetal incomplete atrioventricular block with dexamethasone. J Rheumatol 28 (2001) 373-376
12. Carreira P.E., Gutierrez-Larraya F., and Gomez-Reino J.J. Successful intrauterine therapy with dexamethasone for fetal myocarditis and heart block in a woman with systemic lupus erythematosus. J Rheumatol 20 (1993) 1204-1207
13. Buyon J.P., Waltuck J., Kleinman C., and Copel J. In utero identification and therapy of congenital heart block. Lupus 4 (1995) 116-121
14. Saleeb S., Copel J., Friedman D., and Buyon J.P. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 42 (1999) 2335-2345
15. Raboisson M.J., Fouron J.C., Sonesson S.E., Nyman M., Proulx F., and Gamache S. Fetal Doppler echocardiographic diagnosis and successful steroid therapy of Luciani-Wenckebach phenomenon and endocardial fibroelastosis related to maternal anti-Ro and anti-La antibodies. J Am Soc Echocardiogr 18 (2005) 375-380
16. Strandberg L., Salomonsson S., Bremme K., Sonesson S.E., and Wahren-Herlenius M. Ro52, Ro60 and La autoantibody levels and Ro52 IgG subclass profiles longitudinally throughout pregnancy in congenital heart block pregnancies. Lupus 15 (2006) 346-353
17. Glickstein J.S., Buyon J., and Friedman D. Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 86 (2000) 236-239
18. Andelfinger G., Fouron J.C., Sonesson S.E., and Proulx F. Reference values for time intervals between atrial and ventricular contractions of the fetal heart measured by two Doppler techniques. Am J Cardiol 88 (2001) 1433-1436 A1438
19. Bergman G., Jacobsson L.A., Wahren-Herlenius M., and Sonesson S.E. Doppler echocardiographic and electrocardiographic atrioventricular time intervals in newborn infants: evaluation of techniques for surveillance of fetuses at risk for congenital heart block. Ultrasound Obstet Gynecol 28 (2006) 57-62
20. Van Bergen A.H., Cuneo B.F., and Davis N. Prospective echocardiographic evaluation of atrioventricular conduction in fetuses with maternal Sjögren's antibodies. Am J Obstet Gynecol 191 (2004) 1014-1018
21. Brucato A., Frassi M., Franceschini F., Cimaz R., Faden D., Pisoni M.P., Muscara M., Vignati G., Stramba-Badiale M., Catelli L., et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 44 (2001) 1832-1835
22. Buyon J.P., Askanase A.D., Kim M.Y., Copel J.A., and Friedman D.M. Identifying an early marker for congenital heart block: when is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis Rheum 52 (2005) 1341-1342
23. Rein A.J., Mevorach D., Perles Z., Shovali A., and Elchalal U. Fetal first-degree heart block, or where to set the confidence limit: comment on the article by Sonesson et al. Arthritis Rheum 52 (2005) 366 author reply 366-368
24. Nii M, Hamilton RM, Fenwick L, Kingdom JC, Roman KS, Jaeggi ET: Assessment of fetal atrio-ventricular time intervals by tissue doppler and pulse doppler echocardiography: normal values and correlation with fetal electrocardiography. Heart 2006, in press.
25. Jaeggi E.T., Silverman E.D., Yoo S.J., and Kingdom J. Is immune-mediated complete fetal atrioventricular block reversible by transplacental dexamethasone therapy?. Ultrasound Obstet Gynecol 23 (2004) 602-605
26. Breur J.M., Visser G.H., Kruize A.A., Stoutenbeek P., and Meijboom E.J. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 24 (2004) 467-472
27. Wolin S.L., and Cedervall T. The La protein. Annu Rev Biochem 71 (2002) 375-403
28. Chen X., and Wolin S.L. The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity. J Mol Med 82 (2004) 232-239
29. Espinosa A., Zhou W., Ek M., Hedlund M., Brauner S., Popovic K., Horvath L., Wallerskog T., Oukka M., Nyberg F., et al. The Sjögren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 176 (2006) 6277-6285. [Ro52] is shown to be an E3 ligase, and to be RING-domain dependent. B cells stably transfected with Ro52 show that the protein is involved in the regulation of cell growth and apoptosis.
30. Wada K., and Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 339 (2006) 415-421. [Ro52] is demonstrated to autoubiquitinate in vitro, and the role of the RING domain confirmed by point mutation of a zinc-coordinating cysteine.
31. Ottosson L., Hennig J., Espinosa A., Brauner S., Wahren-Herlenius M., and Sunnerhagen M. Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjogren's syndrome. Mol Immunol 43 (2006) 588-598
32. 2+-dependent subdomain interactions involving autoantigenic epitopes in the Ring-B-box-coiled-coil (RBCC) region of Ro52. J Biol Chem 280 (2005) 33250-33261
33. Julkunen H., Miettinen A., Walle T.K., Chan E.K., and Eronen M. Autoimmune response in mothers of children with congenital and postnatally diagnosed isolated heart block: a population based study. J Rheumatol 31 (2004) 183-189
34. Salomonsson S., Dörner T., Theander E., Bremme K., Larsson P., and Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 46 (2002) 1233-1241
35. Fritsch C., Hoebeke J., Dali H., Ricchiuti V., Isenberg D.A., Meyer O., and Muller S. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther 8 (2005) R4
36. Salomonsson S., Sonesson S.E., Ottosson L., Muhallab S., Olsson T., Sunnerhagen M., Kuchroo V.K., Thoren P., Herlenius E., and Wahren-Herlenius M. Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 201 (2005) 11-17. Monoclonal human Ro52 antibodies cloned from patients and specific for the p200 epitope are shown to bind to the cell surface of cardiomyocytes, induce dysregulation of calcium homeostasis, causing calcium overload and subsequent apoptosis.
37. Clancy R.M., Buyon J.P., Ikeda K., Nozawa K., Argyle D.A., Friedman D.M., and Chan E.K. Maternal antibody responses to the 52-kd SSA/Ro p200 peptide and the development of fetal conduction defects. Arthritis Rheum 52 (2005) 3079-3086
38. Gordon P., Khamashta M.A., Rosenthal E., Simpson J.M., Sharland G., Brucato A., Franceschini F., De Bosschere K., Meheus L., Meroni P.L., et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 31 (2004) 2480-2487
39. Boutjdir M. Molecular and ionic basis of congenital complete heart block. Trends Cardiovasc Med 10 (2000) 114-122
40. 1D L-type calcium channel is shown to be expressed in human heart, and its activity is inhibited by human Ro/La antibody containing sera.
41. Hu K., Qu Y., Yue Y., and Boutjdir M. Functional basis of sinus bradycardia in congenital heart block. Circ Res 94 (2004) e32-e38
42. Eftekhari P., Salle L., Lezoualc'h F., Mialet J., Gastineau M., Briand J.P., Isenberg D.A., Fournie G.J., Argibay J., Fischmeister R., et al. Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 30 (2000) 2782-2790
43. Eftekhari P., Roegel J.C., Lezoualc'h F., Fischmeister R., Imbs J.L., and Hoebeke J. Induction of neonatal lupus in pups of mice immunized with synthetic peptides derived from amino acid sequences of the serotoninergic 5-HT4 receptor. Eur J Immunol 31 (2001) 573-579
44. Kamel R., Eftekhari P., Clancy R., Buyon J.P., and Hoebeke J. Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun 25 (2005) 72-76
45. Salomonsson S., Ottosson L., Safsten P., Hof D., Brauner H., Sunnerhagen M., Raats J., and Wahren-Herlenius M. Cloning and characterization of two human Ro52-specific monoclonal autoantibodies directed towards a domain associated with congenital heart block. J Autoimmun 22 (2004) 167-177
46. Ottosson L., Salomonsson S., Hennig J., Sonesson S.E., Dorner T., Raats J., Kuchroo V.K., Sunnerhagen M., and Wahren-Herlenius M. Structurally derived mutations define congenital heart block-related epitopes within the 200-239 amino acid stretch of the Ro52 protein. Scand J Immunol 61 (2005) 109-118
47. Tran H.B., Ohlsson M., Beroukas D., Hiscock J., Bradley J., Buyon J.P., and Gordon T.P. Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system: a clue to the pathogenesis of congenital heart block. Arthritis Rheum 46 (2002) 202-208
48. Tran H.B., Macardle P.J., Hiscock J., Cavill D., Bradley J., Buyon J.P., and Gordon T.P. Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum 46 (2002) 1572-1579
49. Neufing P.J., Clancy R.M., Jackson M.W., Tran H.B., Buyon J.P., and Gordon T.P. Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum 52 (2005) 3934-3942
50. Solomon D.G., Rupel A., and Buyon J.P. Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus 12 (2003) 646-647
51. Bolstad A.I., and Jonsson R. Genetic aspects of Sjogren's syndrome. Arthritis Res 4 (2002) 353-359
52. Clancy R.M., Backer C.B., Yin X., Kapur R.P., Molad Y., and Buyon J.P. Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-α and TGF-β1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol 171 (2003) 3253-3261. The frequency of the TGF allele Leu10 was significantly increased in children with congenital heart block compared with their unaffected siblings, whereas TNF-308A was significantly increased in all forms of neonatal lupus. TGF, but not TNF, expression was found in the septal region of the heart in fetuses that died from congenital heart block.
53. Stevens A.M., Hermes H.M., Rutledge J.C., Buyon J.P., and Nelson J.L. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 362 (2003) 1617-1623. Maternal microchimerism is found in fetal hearts of children with congenital heart block, suggesting that these cells might be important in the pathogenesis of the disease.